News Focus
News Focus
icon url

wadegarret

11/20/25 2:54 PM

#127743 RE: researcher59 #127742

R59- JAZZ

What do you think of this one, after the blockbuster phase 3 results for Ziihera ? The only major drug competitor I know of is Roche's Vyloy, and that drug has way more serious side effects that caused 20% to discontinue vs 2.5% for Ziihera.
icon url

hweb2

11/20/25 3:51 PM

#127745 RE: researcher59 #127742

Yikes that was one ugly market reversal today. How much would the markets have been down on a bad report from NVDA??